Daiichi Sankyo

Photo
07.08.2024 • News

Daiichi Sankyo and MSD Expand Global Collaboration

Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody drug conjugates to include MSD’s MK-6070, a compound MSD obtained through its recent acquisition of Harpoon Therapeutics.

Photo
20.10.2023 • News

Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide

Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where Daiichi Sankyo retains exclusive rights. Merck to pay Daiichi Sankyo up to €20.8 billion for the collaboration.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.